Comparison of Micro- and Macrovascular Disease(s) in People With T2D, Who Have Moderate to Severe Acanthosis Nigricans vs. Those Who do Not Have Acanthosis Nigricans - Trial NCT06386939
Access comprehensive clinical trial information for NCT06386939 through Pure Global AI's free database. This phase not specified trial is sponsored by Diabetes Foundation, India and is currently Recruiting. The study focuses on Type 2 Diabetes Mellitus With Complication. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Diabetes Foundation, India
Timeline & Enrollment
N/A
May 01, 2024
Nov 30, 2025
Primary Outcome
Moderate to Severe Acanthosis Nigricans increases diabetes complications
Summary
Hypothesis: Moderate to severe acanthosis nigricans in people with T2D is associated with
 higher magnitude of complication than people who do not have acanthosis nigricans.
 
 Objectives: To correlate moderate to severe acanthosis nigricans with diabetes complication
 
 Methodology:
 
 T2DM patient will be recruited from endocrine OPD
 
 1. Clinical History and Examination:
 
 1. General Physical Examination: Height, weight, waist circumference, hip circumference,
 BMI, Blood Pressure, Hand grip. Acanthosis Nigricans.
 
 2. Complications Assessment: Patient will be analysed for:
 
 Micro Vascular
 
 (a) Diabetic retinopathy (i) Mild NPDR (ii) Mod NPDR (iii) Macular Edema / CSME (b)
 Neuropathy (Mild/Mod/Severe) (c) Chronic Kidney Disease (i) Micro/Macro albumin urea (ii)
 Increased Creatinine (iii) Decreased eGFR
 
 Macro Vascular
 
 1. Low ABI/PAD
 
 2. CVD-MI/PTCA/CABG/Heart Failure
 
 3. CVS-Stroke/ TIA/Carotid Blockage 50%
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06386939
Non-Device Trial